Full history for every metric is available with a Kvantra account

Stock profile
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
9.84B
Currency USD
KvantraRankAbout55
IValue54
IIQuality38
IIIMomentum82
Current price
115.31 USD-3.42%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m34734779473910299
Operating profit$m-349-405
Net profit$m-46-100-155-147-224-311-349-317
EPS reported$-3.69-3.63
Operating cashflow per share$-2.76-2.87
Capex per share$0.020.01
FCF per share$-2.78-2.89
Free cash flow$m-234-289
Net debt$m-766-895
Book value equity$m1,5801,615
Book value per share$18.7216.13
Number of sharesm84.39100.1
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx4.166.10
P/S LTMx167.5196.30
P/FCF LTMx-28.02-34.08
EV/EBITDA LTMx-20.76-26.22
EV/Sales LTMx160.5087.55
Earnings Yield LTM%-4.74%-2.88%
FCF Yield%-3.57%-2.93%
Quality
ROE%-19.71%-22.39%
ROIC%-20.88%-23.94%
Operating margin%-891.33%-396.08%
Gross margin%100.00%174.52%
FCF/Sales%-597.81%-282.61%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%-16.72%+133.74%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-2.85-3.77
Net Debt/EBITDAx0.910.87
EBIT/Net interestx-1,403.21-1,483.11
Net debt/market cap%-11.67%-9.09%
Net debt/Equityx-0.48-0.55
Gross debt/equityx0.050.05

ETFs that hold Kymera Therapeutics

FundTickerPosition#Weight
Harbor Human Capital Factor US Small Cap ETFHAPS12.30%

Funds with Kymera Therapeutics among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price115.31 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Kymera Therapeutics, Inc. (KYMR)

KYMR · NASDAQ · Healthcare
115.31 USD-3.42%
Sign up to track this stock
Benchmarks
KvantraRank55
Market cap9.84B
P/E NTMN/A
P/E TTMN/A
KvantraRank?55 / 100
Value
54
Quality
38
Momentum
82
Financialsin USD
20242025TTM2026E
ETFs that hold Kymera Therapeutics
FundTickerPosition#Weight
Harbor Human Capital Factor US Small Cap ETFHAPS12.30%

Funds with Kymera Therapeutics among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current115.31 USD
Upside
Price consensus
Last year average price target
Current price115.31 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free